Sarepta Rumors Drive Shares Up

Sarepta (Nasdaq: SRPT  ) rumors are once again swirling, and shares are up 3% as a result. The company is often talked about as a possible candidate for a buyout because of its drug Eteplirsen, which has had incredible results treating Duchenne muscular dystrophy. The 3% jump today was due to a presentation by Vertex Pharmaceuticals (Nasdaq: VRTX  ) on its cystic fibrosis drug Kalydeco, which had several slides discussing Eteplirsen. Vertex has been mentioned in passing before as a possible interested party in Sarepta. Shares currently trade around $30 per share, but a recent upgrade from Piper Jaffray pegged the stock to go to anywhere between $60 and $80 in the short term, and possibly as high as $160.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2131447, ~/Articles/ArticleHandler.aspx, 4/20/2014 12:34:41 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement